Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Does cannabis hold the key to treating cardiometabolic disease?

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Steffens S et al. (2005) Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434: 782–786

    CAS  Article  Google Scholar 

  2. Van Gaal LF et al. (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365: 1389–1397

    CAS  Article  Google Scholar 

  3. Di Marzo V et al. (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3: 771–784

    CAS  Article  Google Scholar 

  4. Osei-Hyiaman D et al. (2005) Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115: 1298–1305

    CAS  Article  Google Scholar 

  5. Klein TW (2005) Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5: 400–411

    CAS  Article  Google Scholar 

  6. Roth MD (2005) Pharmacology: marijuana and your heart. Nature 434: 708–709

    CAS  Article  Google Scholar 

  7. Lau DCW et al. (2005) Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol 288: 2031–2041

    Article  Google Scholar 

  8. Batkai S et al. (2004) Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110: 1996–2002

    CAS  Article  Google Scholar 

  9. Le Foll B et al. (2004) Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport 15: 2139–2143

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Subodh Verma.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Szmitko, P., Verma, S. Does cannabis hold the key to treating cardiometabolic disease?. Nat Rev Cardiol 3, 116–117 (2006). https://doi.org/10.1038/ncpcardio0504

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0504

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing